Longer RFS with Nivolumab Than with Ipilimumab Among Patients with Resected Stage IIIB-C or Stage IV Melanoma By Ogkologos - February 2, 2026 122 0 Facebook Twitter Google+ Pinterest WhatsApp Final data from the CheckMate 238 study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR How Breast Cancer Risk Assessment Tools Work June 27, 2024 T-DM1 Approval Expanded to Include Some Women with Early-Stage HER2-Positive Breast... May 23, 2019 Silence Speaks Volumes June 16, 2020 ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of... July 1, 2025 Load more HOT NEWS Camrelizumab Plus Rivoceranib Improves Survival Compared with Sorafenib in First-Line Treatment... Cancer Patient’s Appetite Increases And His Blood Pressure Lowers After A... EMA Recommends Granting a Marketing Authorisation for Inavolisib TRACERx: Using blood tests to track lung cancer
